These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 7998297)

  • 1. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score.
    Oellerich M; Hartmann H; Ringe B; Burdelski M; Lautz HU; Pichlmayr R
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1116-9. PubMed ID: 8442062
    [No Abstract]   [Full Text] [Related]  

  • 3. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE; Miguez C; Rubio M; Bartellini M; Levi D; Podestá A; Niselman V; Terg R
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoethylglycinexylidide production as a measure in predicting hepatic histology.
    Forte G; Rocco P; Costanzo A; Grimaldi E; Rossi R; Bottiglieri ME; Biceglia O; Zampella G
    Ital J Gastroenterol; 1994 May; 26(4):159-62. PubMed ID: 7949258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoethylglycinexylidide (MEGX) as a liver function test in cirrhosis.
    Bhise SB; Dias RJ
    Indian J Gastroenterol; 2007; 26(4):167-9. PubMed ID: 17986743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis.
    Arrigoni A; Gindro T; Aimo G; Cappello N; Meloni A; Benedetti P; Molino GP; Verme G; Rizzetto M
    Hepatology; 1994 Aug; 20(2):383-7. PubMed ID: 8045499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
    Reichel C; Nacke A; Sudhop T; Wienkoop G; Lüers C; Hahn C; Pohl C; Spengler U; Sauerbruch T
    Hepatology; 1997 Jun; 25(6):1323-7. PubMed ID: 9185746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of one-year pretransplant survival in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Binder L; Pichlmayr R
    Hepatology; 1991 Dec; 14(6):1029-34. PubMed ID: 1959850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation].
    Reichel C; Wienkoop G; Nacke A; Spengler U
    Dtsch Med Wochenschr; 1995 Feb; 120(6):179-83. PubMed ID: 7851289
    [No Abstract]   [Full Text] [Related]  

  • 10. Lidocaine elimination in patients with liver cirrhosis.
    Wójcicki J; Kozłowski K; Droździk M; Wójcicki M
    Acta Pol Pharm; 2002; 59(4):321-4. PubMed ID: 12403308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic lidocaine metabolism and liver histology.
    Fabbri A; Bianchi GP; Marchesini G
    Hepatology; 1995 Jun; 21(6):1761-2. PubMed ID: 7768525
    [No Abstract]   [Full Text] [Related]  

  • 12. A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine.
    Corpataux JM; Munafo A; Buclin T; Biollaz J; Mosimann F
    Transplant Proc; 2001 Jun; 33(4):2557-62. PubMed ID: 11406248
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurement of liver function for patients with cirrhosis by 13C-methacetin breath test compared with Child-Pugh score and routine liver function tests.
    Liu YX; Huang LY; Wu CR; Cui J
    Chin Med J (Engl); 2006 Sep; 119(18):1563-6. PubMed ID: 16996011
    [No Abstract]   [Full Text] [Related]  

  • 14. MEGX: from bench to bedside.
    Sanyal AJ; Zfass AM
    Am J Gastroenterol; 1992 Jul; 87(7):919-21. PubMed ID: 1615952
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of lidocaine metabolite formation as a quantitative liver function test in children.
    Gremse DA; A-Kader HH; Schroeder TJ; Balistreri WF
    Hepatology; 1990 Sep; 12(3 Pt 1):565-9. PubMed ID: 2401461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation.
    Luketic VA; Shiffman ML; Fisher RA; Sanyal AJ; Purdum PP; Posner MP
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1072-4. PubMed ID: 8442046
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
    Shiffman ML; Luketic VA; Sanyal AJ; Duckworth PF; Purdum PP; Contos MJ; Mills AS; Edinboro LE; Poklis A
    Hepatology; 1994 Apr; 19(4):933-40. PubMed ID: 8138268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dynamic liver function study using the lidocaine test].
    Sídlová K; Průsa R
    Cas Lek Cesk; 2000 Sep; 139(19):604-5. PubMed ID: 11192753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between hemodynamic alterations and Child-Pugh Score in patients with cirrhosis.
    Dincer D; Besisk F; Demirkol O; Demir K; Kaymakoglu S; Cakaloglu Y; Okten A
    Hepatogastroenterology; 2005; 52(65):1521-5. PubMed ID: 16201110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lidocaine monoethylglycinexylidide test of liver function.
    Ghent CN; Wall WJ
    Liver Transpl Surg; 1996 May; 2(3):242-5. PubMed ID: 9346657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.